{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:26:37Z","timestamp":1790231197340,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tumors may utilize different strategies to escape T cell immunosurveillance. Besides the overexpression of checkpoint ligands (such as PDL1) or the secretion of immunosuppressive agents, several studies have shown that cancer aberrant sialylation can, through interaction with selected receptors such as those from the Siglec family, neutralize NK and T cell function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, we wanted to take advantage of the presence of inhibitory sialic acid ligands on the tumor cell surface to enhance T cell anti-tumor activity. To this end, we devised a novel chimeric receptor consisting of the extracellular portion of Siglec-7 and the intracellular portion of 41BB, which can convert inhibitory signals into stimulatory ones when expressed in human T-cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This co-stimulatory chimeric switch receptor (CSR), when co-expressed with a tumor-specific TCR, facilitated higher cytokine secretion and activation profiles following co-culture with tumor cells. Additionally, T cells equipped with Siglec-7 CSR demonstrated improved anti-tumor function <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Given the broad expression pattern of Siglec-7 ligands on tumor cells, our data suggest this CSR may act as a general adjuvant to boost TCR T cell function. Overall, this work provides an approach to improve engineered T-cell-based cancer treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1536868","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:30:38Z","timestamp":1747114238000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR"],"prefix":"10.3389","volume":"16","author":[{"given":"Shiran","family":"Didi-Zurinam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erel","family":"Katzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1021\/cr000407m","article-title":"Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective","volume":"102","author":"Angata","year":"2002","journal-title":"Chem Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-023-00035-7","article-title":"Bacterial sialic acid catabolism at the host-microbe interface","volume":"61","author":"Kim","year":"2023","journal-title":"J Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1039\/D2BM01595A","article-title":"Multivalent sialic acid materials for biomedical applications","volume":"11","author":"Cao","year":"2023","journal-title":"Biomater Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2017.276.issue-1","article-title":"Viewing Siglecs through the lens of tumor immunology","volume":"276","author":"Fraschilla","year":"2017","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cancers10060207","article-title":"Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities","volume":"10","author":"Rodrigues","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01074-1","article-title":"Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection","volume":"20","author":"Pinho","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41573-021-00160-1","article-title":"Author Correction: The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans","volume":"20","author":"Smith","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/cells8101125","article-title":"Siglecs in brain function and neurological disorders","volume":"8","author":"Siddiqui","year":"2019","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak","year":"2023","journal-title":"Mol Aspects Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403538200","article-title":"Negative regulation of T cell receptor signaling by Siglec-7 (p70\/AIRM) and Siglec-9","volume":"279","author":"Ikehara","year":"2004","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/cells10051260","article-title":"Siglec ligands","volume":"10","author":"Gonzalez-Gil","year":"2021","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.48.34089","article-title":"Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes","volume":"274","author":"Nicoll","year":"1999","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v114.2","article-title":"Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7","volume":"114","author":"Fan","year":"2023","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00018-023-04816-6","article-title":"Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7","volume":"80","author":"van Houtum","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101145","DOI":"10.1016\/j.mam.2022.101145","article-title":"Non-canonical roles of Siglecs: Beyond sialic acid-binding and immune cell modulation","volume":"90","author":"Siddiqui","year":"2023","journal-title":"Mol Aspects Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01047","article-title":"Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer","volume":"10","author":"Daly","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Investigation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.v13.9","article-title":"Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling","volume":"13","author":"van Houtum","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0823","article-title":"Targeting tumor-associated sialic acids using chimeric switch receptors based on siglec-9 enhances the antitumor efficacy of engineered T cells","volume":"12","author":"Eisenberg","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2019.01.007","article-title":"T-cells \u201c\u00e0 la CAR-T(e)\u201d - Genetically engineering T-cell response against cancer","volume":"141","author":"Eisenberg","year":"2019","journal-title":"Adv Drug Delivery Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021288","article-title":"Restoration of CD28 expression in CD28\u2013 CD8+ Memory effector T cells reconstitutes antigen-induced IL-2 production","volume":"198","author":"Topp","year":"2003","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28320","article-title":"Enhanced antitumor activity mediated by human 4-1BB-engineered T cells","volume":"133","author":"Daniel-Meshulam","year":"2013","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s40425-019-0721-y","article-title":"A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function","volume":"7","author":"Hoogi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203085","article-title":"Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity","volume":"191","author":"Ankri","year":"2013","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0103","article-title":"Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers","volume":"9","author":"Tay","year":"2017","journal-title":"Immunotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2741\/4772","article-title":"Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients","volume":"24","author":"Guo","year":"2019","journal-title":"Front Biosci - Landmark"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2017.01212","article-title":"Targeting multiple tumors using T-cells engineered to express a natural cytotoxicity receptor 2-based chimeric receptor","volume":"8","author":"Eisenberg","year":"2017","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103020","article-title":"Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity","volume":"188","author":"Haga-Friedman","year":"2012","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/cells9020273","article-title":"Biological functions and analytical strategies of sialic acids in tumor","volume":"9","author":"Zhou","year":"2020","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23213","article-title":"Targeting glycosylated antigens on cancer cells using siglec-7\/9-based CAR T-cells","volume":"59","author":"Meril","year":"2020","journal-title":"Mol Carcinog"},{"key":"B34","doi-asserted-by":"publisher","first-page":"112475","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3\u2019s enigmatic mechanism of action","volume":"11","author":"Graydon","year":"2020","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00073-7","article-title":"T cell receptor therapeutics hit the immuno-oncology stage","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1901434","article-title":"Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/cancers14081998","article-title":"T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity","volume":"14","author":"Sailer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0046","article-title":"Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy","volume":"20","author":"Yu","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996746","article-title":"Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities","volume":"13","author":"Haas","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12026-009-8113-x","article-title":"The contribution of direct TLR signaling to T cell responses","volume":"45","author":"Rahman","year":"2009","journal-title":"Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04180.x","article-title":"The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells","volume":"12","author":"Magee","year":"2012","journal-title":"Am J Transplantation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp Mol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nri3754","article-title":"Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell","volume":"14","author":"Kambayashi","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-64887-4","article-title":"Discovery of a new sialic acid binding region that regulates Siglec-7","volume":"10","author":"Yamakawa","year":"2020","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.799861","article-title":"The distinct roles of sialyltransferases in cancer biology and onco-immunology","volume":"12","author":"Hugonnet","year":"2021","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-226332","article-title":"The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer\u2013cell subsets associated with high levels of HIV-1 viremia","volume":"114","author":"Brunetta","year":"2009","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6243819","article-title":"The roles of siglec7 and siglec9 on natural killer cells in virus infection and tumour progression","volume":"2020","author":"Zheng","year":"2020","journal-title":"J Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03393-22","article-title":"Siglec-9 restrains antibody-dependent natural killer cell cytotoxicity against SARS-Cov-2","volume":"14","author":"Saini","year":"2023","journal-title":"mBio"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nchembio.1415","article-title":"Glyco-engineering \u201csuper-self","volume":"10","author":"Macauley","year":"2014","journal-title":"Nat Chem Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1536868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:30:39Z","timestamp":1747114239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1536868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1536868"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1536868","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1536868"}}